Identification of gene signature in RNA-Seq hepatocellular carcinoma data by Pareto-optimal cluster algorithm
Gastroenterology and Hepatology from Bed to Bench,
Vol. 15 No. 4 (2022),
3 Mehr 2022
https://doi.org/10.22037/ghfbb.v15i4.2488
Abstract
Aim: This study aimed to detect gene signatures in RNA-sequencing (RNA-seq) data using Pareto-optimal cluster size identification.
Background: RNA-seq has emerged as an important technology for transcriptome profiling in recent years. Gene expression signatures involving tens of genes have been proven to be predictive of disease type and patient response to treatment.
Methods: Data related to the liver cancer RNA-seq dataset, which included 35 paired hepatocellular carcinoma (HCC) and non-tumor tissue samples, was used in this study. The differentially expressed genes (DEGs) were identified after performing pre-filtering and normalization. After that, a multi-objective optimization technique, namely multi-objective optimization for collecting cluster alternatives (MOCCA), was used to discover the Pareto-optimal cluster size for these DEGs. Then, the k-means clustering method was performed on the RNA-seq data. The best cluster, as a signature for the disease, was found by calculating the average Spearman's correlation score of all genes in the module in a pair-wise manner. All analyses were performed in the R 4.1.1 package in virtual space with 100 Gb of RAM memory.
Results: Using MOCCA, eight Pareto-optimal clusters were obtained. Ultimately, two clusters with the greatest average Spearman's correlation coefficient scores were chosen as gene signatures. Eleven prognostic genes involved in HCC's abnormal metabolism were identified. In addition, three differentially expressed pathways were identified between tumor and non-tumor tissues.
Conclusion: These identified metabolic prognostic genes help us to provide more powerful prognostic information and enhance survival prediction for HCC patients. In addition, Pareto-optimal cluster size identification is suggested for gene signature in other RNA-Seq data.
- Hepatocellular carcinoma, gene expression signature, RNA-Seq, clustering
How to Cite
References
Ghouri YA, Mian I, Rowe JH. Review of hepatocellular carcinoma: epidemiology, etiology, and carcinogenesis. J Carcinog. 2017;16:1.
Bray F, Ferlay J, Soerjomataram I, Siegel L, Torre A, Ahmedin D. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394-424.
Petrick JL, Florio AA, Znaor A, Ruggieri D, Laversanne M, Alvarez CS, et al. International trends in hepatocellular carcinoma incidence, 1978–2012. Int J Cancer 2020;147:317-30.
Hoti E, Adam R. Liver transplantation for primary and metastatic liver cancers. Transpl Int 2008;21:1107-17.
Ayuso C, Rimola J, Vilana R, Burrel M, Darnell A, García-Criado Á, et al. Diagnosis and staging of hepatocellular carcinoma (HCC): current guidelines. Eur J Radiol 2018;101:72-81.
Rashed WM, Kandeil MAM, Mahmoud MO, Ezzat S. Hepatocellular Carcinoma (HCC) in Egypt: a comprehensive overview. J Egypt Natl Cancer Inst 2020;32:1-11.
Hertl M, Cosimi AB. Liver transplantation for malignancy. Oncologist 2005;10:269-81.
Van't Veer LJ, Bernards R. Enabling personalized cancer medicine through analysis of gene-expression patterns. Nature 2008;452:564-70.
Zhao S, Ye Z, Stanton R. Misuse of RPKM or TPM normalization when comparing across samples and sequencing protocols. RNA 2020;26:903-9.
De Souto MC, Costa IG, De Araujo DS, Ludermir TB, Schliep A. Clustering cancer gene expression data: a comparative study. BMC bioinform 2008;9:1-14.
Maulik U, Mukhopadhyay A, Bandyopadhyay S. Combining pareto-optimal clusters using supervised learning for identifying co-expressed genes. BMC bioinform 2009;10:1-16.
Runkler TA, editor Pareto optimality of cluster objective and validity functions. 2007 IEEE International Fuzzy Systems Conference; 2007: IEEE.
Li WC, Bai DL, Xu Y, Chen H, Ma R, Hou WB, et al. Identification of differentially expressed genes in synovial tissue of rheumatoid arthritis and osteoarthritis in patients. J Cell Biochem 2019;120:4533-44.
Zhang X, Yin S, Ma K. Bioinformatics analysis of different candidate genes involved in hepatocellular carcinoma induced by HepG2 cells or tumor cells of patients. J Int Med Res 2020;48:0300060520932112.
Georgila K, Vyrla D, Drakos E. Apolipoprotein AI (ApoA-I), immunity, inflammation and cancer. Cancers 2019;11:1097.
Mustafa MG, Petersen JR, Ju H, Cicalese L, Snyder N, Haidacher SJ, et al. Biomarker discovery for early detection of hepatocellular carcinoma in hepatitis C–infected patients. Mol Cell Proteom 2013;12:3640-52.
Ren L, Yi J, Li W, Zheng X, Liu J, Wang J, et al. Apolipoproteins and cancer. Cancer Med 2019;8:7032-43.
Huang D, Yuan W, Li H, Li S, Chen Z, Yang H. Identification of key pathways and biomarkers in sorafenib‑resistant hepatocellular carcinoma using bioinformatics analysis. Exp Ther Med 2018;16:1850-8.
Zhong H, Xiao M, Zarkovic K, Zhu M, Sa R, Lu J, et al. Mitochondrial control of apoptosis through modulation of cardiolipin oxidation in hepatocellular carcinoma: a novel link between oxidative stress and cancer. Free Radic Biol Med 2017;102:67-76.
Wang M, Zhang G, Zhang Y, Cui X, Wang S, Gao S, et al. Fibrinogen Alpha Chain Knockout Promotes Tumor Growth and Metastasis through Integrin–AKT Signaling Pathway in Lung Cancer. Mol Cancer Res 2020;18:943-54.
Mosesson MW. Fibrinogen and fibrin structure and functions. J Thromb Haemost 2005;3:1894-904.
Zhang X, Wang F, Huang Y, Ke K, Zhao B, Chen L, et al. FGG promotes migration and invasion in hepatocellular carcinoma cells through activating epithelial to mesenchymal transition. Cancer Manag Res 2019;11:1653.
Qin X-Y, Hara M, Arner E, Kawaguchi Y, Inoue I, Tatsukawa H, et al. Transcriptome analysis uncovers a growth-promoting activity of Orosomucoid-1 on hepatocytes. EBioMedicine 2017;24:257-66.
Yang Q, Graham TE, Mody N, Preitner F, Peroni OD, Zabolotny JM, et al. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature 2005;436:356-62.
Wang Y, Wang Y, Zhang Z. Adipokine RBP4 drives ovarian cancer cell migration. J Ovarian Res 2018;11:1-10.
O’Flanagan CH, Bowers LW, Hursting SD. A weighty problem: metabolic perturbations and the obesity-cancer link. Horm Mol Biol Clin Investig 2015;23:47-57.
Wang D-b, Li X, Lu X-k, Sun Z-y, Zhang X, Chen X, et al. Transthyretin (TTR) suppressed tumor progression in non-small cell lung cancer by inactivating MAPK/ERK pathway. Cancer Biother Radiopharm 2021.
Kozak KR, Su F, Whitelegge JP, Faull K, Reddy S, Farias‐Eisner R. Characterization of serum biomarkers for detection of early stage ovarian cancer. Proteomics 2005;5:4589-96.
Jacobsson B, Collins V, Grimelius L, Pettersson T, Sandstedt B, Carlström A. Transthyretin immunoreactivity in human and porcine liver, choroid plexus, and pancreatic islets. J Histochem Cytochem 1989;37:31-7.
Imanishi T. Clinical and experimental studies on the profiles of serum proteins in acute hepatic injury. Gastroenterolo Jpn 1981;16:493-505.
Zhang Y, Chen X, Cao Y, Yang Z. C8B in Complement and Coagulation Cascades Signaling Pathway is a predictor for Survival in HBV-Related Hepatocellular Carcinoma Patients. Cancer Manag Res 2021;13:3503.
Castiblanco-Valencia MM, Fraga TR, Pagotto AH, de Toledo Serrano SM, Abreu PAE, Barbosa AS, et al. Plasmin cleaves fibrinogen and the human complement proteins C3b and C5 in the presence of Leptospira interrogans proteins: a new role of LigA and LigB in invasion and complement immune evasion. Immunobiology 2016;221:679-89.
Nilsson B, Teramura Y, Ekdahl KN. The role and regulation of complement activation as part of the thromboinflammation elicited in cell therapies. Mol Immunol 2014;61:185-90.
Palacios-Acedo AL, Mège D, Crescence L, Dignat-George F, Dubois C, Panicot-Dubois L. Platelets, thrombo-inflammation, and cancer: collaborating with the enemy. Front Immunol 2019;10:1805.
Wang B, Zhu J, Ma X, Wang H, Qiu S, Pan B, et al. Platelet activation status in the diagnosis and postoperative prognosis of hepatocellular carcinoma. Clin Chim Acta 2019;495:191-7.
Menter DG, Kopetz S, Hawk E, Sood AK, Loree JM, Gresele P, et al. Platelet “first responders” in wound response, cancer, and metastasis. Cancer Metastasis Rev 2017;36:199-213.
Xue YH, Zhang XF, Dong QZ, Sun J, Dai C, Zhou HJ, et al. Thrombin is a therapeutic target for metastatic osteopontin‐positive hepatocellular carcinoma. Hepatology 2010;52:2012-22.
Fanale D, Amodeo V, Caruso S. The interplay between metabolism, PPAR signaling pathway, and cancer. PPAR Res 2017;2017:1830626.
Mello T, Materozzi M, Galli A. PPARs and mitochondrial metabolism: from NAFLD to HCC. PPAR Res 2016;2016.
- Abstract Viewed: 142 times
- PDF Downloaded: 85 times